ST. PAUL, Minn. & NEW YORK--(BUSINESS WIRE)--Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) and Calyxt, Inc. announced today that Calyxt has commenced a proposed initial public offering of 6,060,606 shares of Calyxt’s common stock pursuant to a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC). In connection with the offering, Calyxt intends to grant the underwriters an option to purchase up to 909,091 additional shares of common stock to cover over-allotments. The estimated price range for the initial public offering is $15.00 to $18.00 per share of common stock, which would result in gross proceeds of $100.0 million at the midpoint of the estimated price range. Calyxt has applied to list its common stock on the NASDAQ under the ticker symbol “CLXT.”
Calyxt is Cellectis’ 100% owned gene editing agriculture company. Cellectis intends to retain majority ownership of Calyxt.
Citigroup, Jefferies and Wells Fargo Securities are acting as joint book-running managers for the proposed offering. BMO Capital Markets and Ladenburg Thalmann are acting as co-managers.